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Randomised controlled trial of
azithromycin in smokers with asthma
To the Editor:
Smokers with asthma have poor symptom control, accelerated decline in lung function and an attenuated
response to corticosteroids compared to nonsmokers with asthma [1]. There is an unmet need for
alternative or additional drugs for smokers with asthma who are unable to stop smoking [2]. Macrolide
antibiotics have anti-inflammatory activity [3] and in clinical studies there is good evidence for efficacy in
the treatment of diffuse pan-bronchiolitis and cystic fibrosis, as well as in preventing chronic rejection after
lung transplantation [4, 5]. In asthma, chronic treatment is associated with a reduction in bronchial
hyperreactivity in mild-to-moderate asthma [6] and in exacerbation rates in non-eosinophilic severe asthma
[7]. To date, no studies have examined the efficacy of macrolide antibiotics exclusively in current smokers
with asthma.
A randomised double-blind parallel-group trial compared azithromycin, 250 mg per day, with placebo for
12 weeks. All subjects were aged 18–70 years, were current smokers (o5 pack-years history) with chronic
asthma (.1 year duration; defined by international criteria [8]) and had to be free of exacerbation and
respiratory tract infection for a minimum 6-week period prior to randomisation. A baseline visit was
performed following a 4-week run-in period on inhaled corticosteroid (ICS) therapy equivalent to 400 mg
beclometasone ¡ a long-acting b2-agonist (LABA). Ethical approval was obtained and all subjects provided
written informed consent. Study visits were performed at 4, 8 and 12 weeks. Clinic visit peak expiratory
flow (PEF) after 12 weeks treatment was the primary outcome measure. A sample size of 68 was calculated
to have an 80% power to detect a mean difference of 25 L?min-1 in change from baseline to 12 weeks in
morning PEF, the primary end-point [9], assuming a standard deviation of changes of 36 L?min-1 using a
two-sample t-test with a 5% two-sided significance level. Recruitment of 80 patients was planned to ensure
that 68 patients completed the study. 77 subjects were randomised with 71 completing the study. Other
measures of airway responsiveness PC20 (provocation concentration of methacholine causing a 20% fall in
forced expiratory volume in 1 s (FEV1)), inflammation (exhaled nitric oxide fraction at 50 mL?s-1 (FeNO50)/
induced sputum/blood and sputum supernatant biomarkers), symptom control (Asthma Control
Questionnaire (ACQ) [10] and Leicester Cough Questionnaire (LCQ) [11]) and quality of life (Asthma
Quality of Life Questionnaire (AQLQ) [10]) were assessed during the study. PEF was recorded using Piko-1
electronic peak flow meters (nSpire, Hertford, UK) and symptoms were recorded in a validated diary card
[10]. Bacteriological and virological analysis of induced sputum was also undertaken. All statistical tests
were two-sided and used a significance level of 5%. All data was analysed using SAS (version 9.2; SAS
Institute, Cary, NC, USA). QTc was also measured at baseline and 12 weeks.
Baseline demographic data and clinical characteristics of the patients were comparable and the two groups
were well balanced. Placebo versus azithromycin groups: age 42.8¡9.4 years versus 46.4¡8.8 years; male
sex 17 (44.7%) versus 20 (51.3%); smoking history 23.6¡15.8 pack-years versus 28.6¡16.4 pack-years;
duration of asthma 24.6¡12.6 years versus 18.8¡12.5 years; atopic 23 (60.1%) versus 27 (69.2%); median
(interquartile range) total IgE 103 (38–291) IU?mL-1 versus 165 (48–254) IU?mL-1; use of ICS at screening
31 (81.6%) versus 35 (89.7%); equivalent beclomethasone dose at screening 709¡564 mg versus
603¡457 mg; use of LABA at randomisation 18 (47.4%) versus 15 (38.5%); pre-bronchodilator FEV1
81.0¡16.8% predicted versus 78.3¡16.4% pred; post-bronchodilator FEV1 89.0¡15.1% pred versus
86.8¡15.2% pred; FEV1 11.3¡9.8% reversibility versus 12.3¡10% reversibility; geometric mean PC20
1.06¡4.10 mg?mL-1 versus 1.07¡3.13 mg?mL-1.
At the final study visit (12 weeks) the change in mean morning clinic PEF (primary outcome), as compared
with baseline, did not differ substantially between the azithromycin and placebo treatment groups (mean
difference -10.3 (95% CI 47.1–26.4 L?min-1), p50.58) (table 1). There was no difference in either pre- or
post-albuterol FEV1 at 4, 8 or 12 weeks between the two groups (table 1). No differences were evident for
PC20 (baseline to 12 week comparison) between the azithromycin or placebo groups (table 1). None of the
self-reported diary card recordings (ACQ, AQLQ or LCQ score) demonstrated any significant differences
between the two groups at 4, 8 or 12 weeks. Noninvasive measures of inflammation, i.e. induced sputum,
sputum supernatant cytokines, peripheral blood cytokines and FeNO50, did not demonstrate any substantial
improvements after 12-weeks of treatment with azithromycin (table 1). Bacterial colony counts did not
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demonstrate any treatment difference between the placebo and azithromycin groups (p50.66, data not
shown). PCR for Mycoplasma pneumonia and Chlamydophila pneumoniae were negative at both baseline
and 12 weeks. QTc was unchanged following 12 weeks of treatment with azithromycin.
No suspected unexpected serious adverse events occurred during the reporting period of the study.
Compliance assessed by capsule count was .90% in each group.
In the first randomised controlled study of azithromycin in smokers with asthma we found that there were
no clinically important improvements in both the primary end-point and morning PEF, and in a range of
secondary clinical outcomes including ACQ score, AQLQ score, spirometry and airway responsiveness, as
well as measures of airway inflammation after 12 weeks of treatment. The median ACQ score of the
participants recruited to the study was raised at 1.7 indicating that they had poorly controlled disease and
scope for clinical improvement. We believe that the choice of a different macrolide from azithromycin or a
different dose of azithromycin is unlikely to have altered our findings. This study was powered to test the
hypothesis on the primary end-point, PEF. We exceeded our minimum recruitment target ensuring
adequate numbers completed the study. The lack of response to treatment was such that recruiting greater
numbers would be unlikely to affect either the primary end-point or the majority of secondary analyses.
Taken together these findings indicate that short-term therapy with azithromycin does not improve lung
function or other indices of current asthma control of smokers with mild-to-moderate asthma who are already
receiving treatment with inhaled corticosteroids. This is supported by a recent study where 6 months of
treatment with azithromycin in nonsmokers with severe asthma did not improve lung function [7].
Recently published data reported that azithromycin administered over 1 year reduced the rate of
exacerbations in chronic obstructive pulmonary disease (COPD), although this benefit was not found in
current smokers with COPD, and bronchiectasis was not an exclusion [12, 13]. Moreover, a 6-month study
with azithromycin in nonsmokers with severe asthma powered to measure exacerbation frequency did not
find any statistical difference between treatment and placebo groups [7], although a beneficial effect of
azithromycin on reducing exacerbations was reported in patients with non-eosinophilic asthma [7]. The
smokers with asthma in our study had non-eosinophilic asthma, but did not respond to azithromycin,
although the duration of treatment was not long enough to assess the effects of azithromycin on exacerbations.
In conclusion, we have studied the effects of 12 weeks of azithromycin in smokers with asthma, an
understudied patient group, and provide clear evidence demonstrating lack of efficacy in both clinical and
laboratory outcomes. Further randomised clinical trials exploring new therapies in smokers with asthma
who are unable to stop smoking are required.
@ERSpublications
Daily azithromycin is ineffective in improving indices of asthma control and airway inflammation
in smokers with asthma http://ow.ly/nQjyn
Euan J. Cameron1, Rekha Chaudhuri1, Frances Mair2, Charles McSharry1, Nicola Greenlaw3, Christopher J. Weir3,
Lisa Jolly1, Iona Donnelly1, Katie Gallacher2, Deborah Morrison2, Mark Spears1, Tom J. Evans1, Kenneth Anderson4
and Neil C. Thomson1
1Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, 2General Practice and Primary
Care, Institute of Health and Wellbeing, University of Glasgow, Glasgow, 3Robertson Centre for Biostatistics, University
of Glasgow, Glasgow, and 4Respiratory Medicine, Crosshouse Hospital, Kilmarnock, UK.
Correspondence: N.C. Thomson, Institute of Infection, Immunity and Inflammation, University of Glasgow, Sir Graeme
Davies Building, 120 University Place, Glasgow, G12 8TA, UK. E-mail: neil.thomson@glasgow.ac.uk
Received: June 03 2013 | Accepted after revision: July 10 2013
Support statement: This work was funded by the Medical Research Council UK and supported financially by NHS
Research Scotland (NRS), through the Scottish Primary Care Research Network; study medication (budesonide Easyhalers;
Orion Pharma (UK), Newbury, UK) was purchased with an educational grant from AstraZeneca (London, UK).
Clinical trial: This study is registered at www.Clinicaltrials.gov with identifier number NCT00852579.
Conflict of interest: Disclosures can be found alongside the online version of this article at www.erj.ersjournals.com
References
1 Thomson N, Chaudhuri R. Asthma in smokers: challenges and opportunities. Curr Opin Pulm Med 2009; 15: 39–45.
2 Polosa R, Thomson NC. Smoking and asthma: dangerous liaisons. Eur Respir J 2013; 41: 716–726.
3 Cameron EJ, McSharry C, Chaudhuri R, et al. Long-term macrolide treatment of chronic inflammatory airway
diseases: risks, benefits and future developments. Clin Exp Allergy 2012; 42: 1302–1312.
4 Spagnolo P, Fabbri LM, Bush A. Long-term macrolide treatment for chronic respiratory disease. Eur Respir J 2013;
42: 239–251.
1414
5 Vos R, Vanaudenaerde BM, Verleden SE, et al. A randomised controlled trial of azithromycin to prevent chronic
rejection after lung transplantation. Eur Respir J 2011; 37: 164–172.
6 Sutherland ER, King TS, Icitovic N, et al. A trial of clarithromycin for the treatment of suboptimally controlled
asthma. J Allergy Clin Immunol 2010; 126: 747–753.
7 Brusselle GG, Vanderstichele C, Jordens P, et al. Azithromycin for prevention of exacerbations in severe asthma
(AZISAST): a multicentre randomised double-blind placebo-controlled trial. Thorax 2013; 68: 322–329.
8 Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. GINA, 2010.
www.ginasthma.org
9 Greening A, Ind P, Northfield M, et al. Added salmeterol versus higher-dose corticosteroid in asthma patients with
symptoms on existing inhaled corticosteroid. Lancet 1994; 344: 219–224.
10 Reddel HK, Taylor DR, Bateman ED, et al. An official American Thoracic Society/European Respiratory Society
statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical
practice. Am J Respir Crit Care Med 2009; 180: 59–99.
11 Birring SS, Prudon B, Carr AJ, et al. Development of a symptom specific health status measure for patients with
chronic cough: Leicester Cough Questionnaire (LCQ). Thorax 2003; 58: 339–343.
12 Albert RK, Connett J, Bailey WC, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med 2011;
365: 689–698.
13 Yamaya M, Azuma A, Takizawa H, et al. Macrolide effects on the prevention of COPD exacerbations. Eur Respir J
2012; 40: 485–494.
Eur Respir J 2013; 42: 1412–1415 | DOI: 10.1183/09031936.00093913 | Copyright ERS 2013
ERJ Open articles are open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 3.0.
Use of household cleaning products,
exhaled nitric oxide and lung function in
children
To the Editor:
The application of domestic cleaning agents increases the risk of asthma and respiratory symptoms in adults
[1], in particular when products are applied in spray form [2]. Despite the associations observed in adults,
the potential effects of passive exposure on children’s respiratory health have not been extensively explored.
Analyses of data from birth cohorts have suggested that frequent use of cleaning agents and their use in
spray form increased the risk of wheezing and lower respiratory tract infections (LRTIs) during the first year
of life [3, 4] and the risk of persistent wheezing at school age [5, 6]. By contrast, a cross-sectional study
reported protective effects of using bleach at home on the prevalence of asthma and allergic sensitisation at
school age [7]. Our study investigates the effects of the use of 10 common cleaning products on exhaled
nitric oxide fraction (FeNO) and on lung function (forced vital capacity (FVC) and forced expiratory volume
in 1 s (FEV1)) during childhood in a population-based birth cohort in Menorca, Spain [8].
Recruitment was performed during pregnancy and 482 children were enrolled at birth. Written informed
consent was obtained from all participants and the study was approved by a committee on ethical practice.
Questionnaires on wheezing, asthma, treatment and allergies (rhinitis, eczema or hay fever) were
administered by the mother repeatedly from birth until the age of 10 years. At the age of 10–13 years, FeNO
(NIOX MINO; Aerocrine AB, Solna, Sweden) and forced spirometry (EasyOne; ndd Medical Technologies,
Inc., Andover, MA, USA) testing was carried out. In addition, an interviewer-led questionnaire on the
frequency of use of 10 different cleaning products (bleach, ammonia, polishes or waxes, acids, solvents,
furniture sprays, glass cleaning sprays, degreasing sprays, air freshening sprays, and air freshening plug-in
devices) was carried out. A total of 295 individuals completed the 10-year follow-up visit and the cleaning
products questionnaire and performed the FeNO and/or the lung function test.
For statistical analyses, we computed a combined spray variable incorporating the four sprays (furniture,
glass cleaning, degreasing and air freshening sprays) and a semiquantitative total score for cleaning product
use. The means of the reported days of use per week (never50, ,1 day per week50.5, 1–3 days per week52
and 4–7 days per week55.5) for each product were summed providing a score ranging from 0 (no
exposure) to 55 (exposed to all 10 products used 4–7 days per week). Multivariable linear regression models
were developed to predict log-transformed FeNO concentration and non-transformed levels of FVC and
FEV1. Models were adjusted for sex, age, maternal education, parental smoking indoors, asthma
medication, season of respiratory test measurement, and for height and weight for lung function
measurements only. The coefficients obtained from the log-transformed FeNO models were back-transformed
1415
